令和3年4月16日更新
業績
英文原著、総説（2013年以降）
2021年
・Okemoto-Nakamura Y, Someya K, Yamaji T, Saito K, Takeda M, Hanada K.
“Poliovirus-nonsusceptible Vero cell line for the World Health Organization global action plan”
Sci. Rep. 2021: 11(1): 6746.
doi: 10.1038/s41598-021-86050-3
・Ogawa M, Shirasago Y, Tanida I, Kakuta S, Uchiyama Y, Shimojima M, Hanada K, Saijo M, Fukasawa M.
“Structural basis of antiviral activity of caffeic acid against severe fever with thrombocytopenia syndrome virus.”
J. Infect. Chemother. 2021: 27(2): 397-400.
doi: 10.1016/j.jiac.2020.10.015
・Shimizu Y, Shinoda T, Shirasago Y, Kondoh M, Shinya N, Hanada K, Yagi K, Suzuki T, Wakita T, Kimura-Someya T, Shirouzu M, Fukasawa M.
Occludin-binding single-chain variable fragment and antigen-binding fragment antibodies prevent hepatitis C virus infection.
FEBS Lett. 2021: 595(2): 220-229.
doi: 10.1002/1873-3468.13975.
・Ogawa M, Shimojima M, Saijo M, Fukasawa M.
“Several catechins and flavonols from green tea inhibit severe fever with thrombocytopenia syndrome virus infection in vitro.”
J. Infect. Chemother. 2021: 27(1): 32-39.
doi: 10.1016/j.jiac.2020.08.005.
2020年
・Kawamoto M, Yamaji T, Saito K, Shirasago Y., Satomura K, Endo T, Fukasawa M, Hanada K, Osada N.
“Identification of Characteristic Genomic Markers in Human Hepatoma Huh7 and Huh7.5.1-8 Cell Lines.”
Front. Genet. 2020: 11: 546106.
doi: 10.3389/fgene.2020.546106
・Gewaid H, Aoyagi H, Arita M, Watashi K, Suzuki R, Sakai S, Kumagai K, Yamaji T, Fukasawa M, Kato F, Hishiki T, Mimata A, Sakamaki Y, Ichinose S, Hanada K, Muramatsu M, Wakita T, Aizaki H.
“Sphingomyelin Is Essential for the Structure and Function of the Double-Membrane Vesicles in the Viral RNA Replication Factories.”
J. Virol. 2020: 94(23): e1080-20.
doi: 10.1128/JVI.01080-20.
・Saito K, Fukasawa M, Shirasago Y, Suzuki R, Osada N, Yamaji T, Wakita T, Konishi E, Hanada K.
“Comparative characterization of flavivirus production in two cell lines: Human hepatoma-derived Huh7.5.1-8 and African green monkey kidney-derived Vero.”
PloS one 2020; 15(4): e0232274
doi: 10.1371/journal.pone.0232274
2019年
・Lavie M, Linna L, Moustafa RI, Belouzard S, Fukasawa M, Dubuisson J.
“Role of the cytosolic domain of occludin in trafficking and hepatitis C virus infection.”
Traffic. 2019; 20(10): 753-773.
・Shimizu Y, Yoneda K, Shirasago Y, Suzuki T, Tada M, Ishii-Watabe A, Sugiyama K, Suzuki T, Wakita T, Yagi K, Kondoh M, Fukasawa M.
“ Human-rat chimeric anti-occludin monoclonal antibodies inhibit hepatitis C virus infection.“
Biochem. Biophys. Res. Commun. 2019 Jun 30;514(3): 785-790.
doi: 10.1016/j.bbrc.2019.05.019.
・Shimizu Y, Shirasago Y, Suzuki T, Hata T, Kondoh M, Hanada K, Yagi K, Fukasawa M.
“Characterization of monoclonal antibodies recognizing each extracellular loop domain of occludin.”
J. Biochem. 2019; 188(4): 297-308.
・Chauhan R, Shimizu Y, Watashi K, Wakita T, Fukasawa M, Michalak TI.
“Retrotransposon elements among initial sites of hepatitis B virus integration into human genome in the HepG2-NTCP cell infection model.”
Cancer Genet. 2019; 235-236: 39-56.
doi: 10.1016/j.cancergen.2019.04.060.
・Yumine N, Matsumoto Y, Ohta K, Fukasawa M, Nishio M.
“Claudin-1 inhibits human parainfluenza virus type 2 dissemination.”
Virology. 2019; 531: 93-99.
doi: 10.1016/j.virol.2019.01.031.
・Shirasago Y, Inamori Y, Suzuki T, Tanida I, Suzuki T, Sugiyama K, Wakita T, Hanada K, Fukasawa M.
“Inhibition Mechanisms of Hepatitis C Virus Infection by Caffeic Acid and Tannic Acid.”
Biol. Pharm. Bull. 2019;42(5): 770-777.
・Osawa T, Shimamura T, Saito K, Hasegawa Y, Ishii N, Nishida M, Ando R, Kondo A, Anwar M, Tsuchida R, Hino S, Sakamoto A, Igarashi K, Saitoh K, Kato K, Endo K, Yamano S, Kanki Y, Matsumura Y, Minami T, Tanaka T, Anai M, Wada Y, Wanibuchi H, Hayashi M, Hamada A, Yoshida M, Yachida S, Nakao M, Sakai J, Aburatani H, Shibuya M, Hanada K, Miyano S, Soga T, Kodama T.
“Phosphoethanolamine Accumulation Protects Cancer Cells under Glutamine Starvation through Downregulation of PCYT2.”
Cell Rep. 2019; 29(1): 89 - 103.e7.
doi: 10.1016/j.celrep.2019.08.087
2018年
・Ohashi H, Nishioka K, Nakajima S, Kim S, Suzuki R, Aizaki H, Fukasawa M, Kamisuki S, Sugawara F, Ohtani N, Muramatsu M, Wakita T, Watashi K.
“The aryl hydrocarbon receptor-cytochrome P450 1A1 pathway controls lipid accumulation and enhances the permissiveness for hepatitis C virus assembly.”
J. Biol. Chem. 2018: 293:19559-19571.
doi: 10.1074/jbc.RA118.005033.
・Shirasago Y, Fukazawa H, Aizaki H, Suzuki T, Suzuki T, Sugiyama K, Wakita T, Hanada K, Abe R, Fukasawa M.
“Thermostable hepatitis C virus JFH1-derived variant isolated by adaptation to Huh7.5.1 cells.”
J. Gen. Virol. 2018: 99: 1407-1417.
・Murakami Y, Sugiyama K, Ebinuma H, Nakamoto N, Ojiro K, Chu P-S, Taniki N, Saito Y, Teratani T, Koda Y, Suzuki T, Saito K, Fukasawa M, Ikeda M, Kato N, Kanai T, Saito H.
“Dual effects of the Nrf2 inhibitor for inhibition of hepatitis C virus and hepatic cancer cells.”
BMC Cancer 2018; 18: 680.
doi: 10.1186/s12885-018-4588-y.
・Ogawa M, Shirasago Y, Ando S, Shimojima M, Saijo M, Fukasawa M.
“Caffeic acid, a coffee-related organic acid, inhibits infection by severe fever with thrombocytopenia syndrome virus in vitro.”
J. Infect. Chemother. 2018; 24: 597-601. *
doi: 10.1016/j.jiac.2018.03.005.
doi: 10.1016/j.jiac.2018.11.009.(Corrigendum)
*selected as one of the “Issue Highlights”.
・Shimizu Y, Shirasago Y, Kondoh M, Suzuki T, Wakita T, Hanada K, Yagi K, Fukasawa M.
“Monoclonal antibodies against occludin completely prevented hepatitis C virus infection in a mouse model.”
J. Virol. 2018; 92(8): e02258-17. *
*selected in "Spotlight," a feature in the Journal that highlights research articles of significant interest from the current issue.
・Sakuma C, Sekizuka T, Kuroda M, Kasai F, Saito K, Ikeda M, Yamaji T, Osada N, Hanada K.
“Novel endogenous simian retroviral integrations in Vero cells: Implications for quality control of a human vaccine cell substrate.”
Sci. Rep. 2018; 8(1): 644.
doi: 10.1038/s41598-017-18934-2
・Saito K, Otsuki, N, Takeda, M, Hanada, K
“Liposome Flotation Assay for Studying Interactions Between Rubella Virus Particles and Lipid Membranes.”
Bio. Protoc. 2018; 8(16): e2983.
・Otsuki N, Sakata M, Saito K, Okamoto K, Mori Y, Hanada K, Takeda M.
“Both Sphingomyelin and Cholesterol in the Host Cell Membrane Are Essential for Rubella Virus Entry.”
J. Virol. 2018; 92(1): e01130-17.
2017年
・Takigawa M, Iida M, Nagase S, Suzuki H, Watari A, Tada M, Okada Y, Doi T, Fukasawa M, Yagi K, Kunisawa J, Kondoh M.
“Creation of a Claudin-2 Binder and Its Tight Junction-Modulating Activity in a Human Intestinal Model.”
J. Pharmacol. Exp. Ther. 2017; 363(3): 444-451.
・Hashimoto Y, Fukasawa M, Kuniyasu H, Yagi K, Kondoh M.
“Claudin-targeted drug development using anti-claudin monoclonal antibodies to treat hepatitis and cancer.”
Ann. N.Y. Acad. Sci. 2017; 1397(1): 5-16.
2016年
・Hashimoto Y, Kawahigashi Y, Hata T, Li X, Watari A, Tada M, Ishii-Watabe A, Okada Y, Doi T, Fukasawa M, Kuniyasu H, Yagi K, Kondoh M.
“Efficacy and safety evaluation of claudin-4-targeted antitumor therapy using a human and mouse cross-reactive monoclonal antibody.”
Pharmacol. Res. Perspect. 2016; 4(5): e00266.
doi: 10.1002/prp2.266. Free PMC Article
・Hashimoto Y, Tada M, Iida M, Nagase S, Hata T, Watari A, Okada Y, Doi T, Fukasawa M, Yagi K, Kondoh M.
“Generation and characterization of a human-mouse chimeric antibody against the extracellular domain of claudin-1 for cancer therapy using a mouse model.”
Biochem. Biophys. Res. Commun. 2016; 477(1): 91-5.
doi: 10.1016/j.bbrc.2016.06.025.
・Shirasago Y, Shimizu Y, Tanida I, Suzuki T, Suzuki R, Sugiyama K, Wakita T, Hanada K, Yagi K, Kondoh M, Fukasawa M.
“Occludin-Knockout Human Hepatic Huh7.5.1-8-Derived Cells Are Completely Resistant to Hepatitis C Virus Infection.”
Biol. Pharm. Bull. 2016; 39(5): 839-48.*
* selected as a “Highlighted paper”
* selected for the cover of the issue
2015年
・Nakajima M, Nagase S, Iida M, Takeda S, Yamashita M, Watari A, Shirasago Y, Fukasawa M, Takeda H, Sawasaki T, Yagi K, Kondoh M.
“Claudin-1 Binder Enhances Epidermal Permeability in a Human Keratinocyte Model.”
J. Pharmacol. Exp. Ther. 2015; 354(3): 440-7.
・Yamashita M, Iida M, Tada M, Shirasago Y, Fukasawa M, Nagase S, Watari A, Ishii-Watabe A, Yagi K, Kondoh M.
“Discovery of anti-claudin-1 antibodies as candidate therapeutics against hepatitis C virus.”
J. Pharmacol. Exp. Ther. 2015; 353(1): 112-8.
・Tanida I, Shirasago Y, Suzuki R, Abe R, Wakita T, Hanada K, Fukasawa M.
“Inhibitory Effects of Caffeic Acid, a Coffee-Related Organic Acid, on the Propagation of Hepatitis C Virus.”
Jpn. J. Infect. Dis. 2015; 68(4): 268-75.
doi: 10.7883/yoken.JJID.2014.309.
・Fukasawa M, Nagase S, Shirasago Y, Iida M, Yamashita M, Endo K, Yagi K, Suzuki T, Wakita T, Hanada K, Kuniyasu H, Kondoh M.
“Monoclonal antibodies against extracellular domains of claudin-1 block hepatitis C virus infection in a mouse model.”
J. Virol. 2015; 89(9): 4866-79.
doi: 10.1128/JVI.03676-14. Free PMC Article
・Saito K, Shirasago Y, Suzuki T, Aizaki H, Hanada K, Wakita T, Nishijima M, Fukasawa M.
“Targeting cellular squalene synthase, an enzyme essential for cholesterol biosynthesis, is a potential antiviral strategy against hepatitis C virus.”
J. Virol. 2015; 89(4): 2220-32.
doi: 10.1128/JVI.03385-14. Free PMC Article
・Shirasago Y, Sekizuka T, Saito K, Suzuki T, Wakita T, Hanada K, Kuroda M, Abe R, Fukasawa M.
“Isolation and characterization of an Huh.7.5.1-derived cell clone highly permissive to hepatitis C virus.”
Jpn. J. Infect. Dis. 2015; 68(2): 81-8.
doi: 10.7883/yoken.JJID.2014.231.
2014年
・Ogawa M, Fukasawa M, Satoh M, Hanada K, Saijo M, Uchiyama T, Ando S.
“The intracellular pathogen Orientia tsutsugamushi responsible for scrub typhus induces lipid droplet formation in mouse fibroblasts.”
Microbes Infect. 2014; 16(11): 962-6.
doi: 10.1016/j.micinf.2014.09.004.
・Li X, Iida M, Tada M, Watari A, Kawahigashi Y, Kimura Y, Yamashita T, Ishii-Watabe A, Uno T, Fukasawa M, Kuniyasu H, Yagi K, Kondoh M.
“Development of an anti-claudin-3 and -4 bispecific monoclonal antibody for cancer diagnosis and therapy.”
J. Pharmacol. Exp. Ther. 2014; 351(1): 206-13.
・Sung PS, Murayama A, Kang W, Kim MS, Yoon SK, Fukasawa M, Kondoh M, Kim JS, Kim H, Kato T, Shin EC.
“Hepatitis C virus entry is impaired by claudin-1 downregulation in diacylglycerol acyltransferase-1-deficient cells.”
J. Virol. 2014; 88(16): 9233-44.
doi: 10.1128/JVI.01428-14. Free PMC Article
・Sugiyama K, Ebinuma H, Nakamoto N, Sakasegawa N, Murakami Y, Chu PS, Usui S, Ishibashi Y, Wakayama Y, Taniki N, Murata H, Saito Y, Fukasawa M, Saito K, Yamagishi Y, Wakita T, Takaku H, Hibi T, Saito H, Kanai T.
“Prominent steatosis with hypermetabolism of the cell line permissive for years of infection with hepatitis C virus.”
PLoS One. 2014; 9(4): e94460.
doi: 10.1371/journal.pone.0094460.
・Iwamoto M, Watashi K, Tsukuda S, Aly HH, Fukasawa M, Fujimoto A, Suzuki R, Aizaki H, Ito T, Koiwai O, Kusuhara H, Wakita T.
“Evaluation and identification of hepatitis B virus entry inhibitors using HepG2 cells overexpressing a membrane transporter NTCP.”
Biochem. Biophys. Res. Commun. 2014; 443(3): 808-13.
doi: 10.1016/j.bbrc.2013.12.052.
2013年
・Maehama T, Fukasawa M, Date T, Wakita T, Hanada K.
“A class II phosphoinositide 3-kinase plays an indispensable role in hepatitis C virus replication.“
Biochem. Biophys. Res. Commun. 2013; 440(1): 150-6.
doi: 10.1016/j.bbrc.2013.09.048.
・Fukasawa M, Cornea A, Varlamov O.
“Selective control of SNARE recycling by Golgi retention.”
FEBS Lett. 2013; 587(15): 2377-84.
doi: 10.1016/j.febslet.2013.06.004.
・Murakami Y, Fukasawa M, Kaneko Y, Suzuki T, Wakita T, Fukazawa H.
“Selective estrogen receptor modulators inhibit hepatitis C virus infection at multiple steps of the virus life cycle.”
Microbes Infect. 2013; 15(1): 45-55.
doi: 10.1016/j.micinf.2012.10.003.
和文総説など
・Fukasawa M.
“Anti-hepatitis C virus strategy targeting the entry steps.”
Yakugaku Zasshi. 2019; 139: 89-95.
doi: 10.1248/yakushi.18-00164-5.
・深澤征義
“C型肝炎は治る時代に～これまでの進歩と今後の課題～”
理大 科学フォーラム、2016; 381, 22-27. (3月号)
・Saito K, Fukasawa M.
“Host cholesterol biosynthesis as a potential target for anti-hepatitis C virus strategies”
Seikagaku. 2016; 88(3): 411-5.
・Fukasawa M.
“Anti-hepatitis C virus strategy targeting host entry factor claudin-1.”
Uirusu. 2015; 65(2): 245-254.
https://doi.org/10.2222/jsv.65.245
・ヒト肝がん由来Huh7.5.1-8細胞とアフリカミドリザル腎由来Vero細胞におけるフラビウイルス産生能の比較解析
https://www.niid.go.jp/niid/ja/basic-science/virology/9615-virology-2020-6.html